Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Princip OFFO/LIS) Conserving Submission Under 25 U.S. Approved for use through 3/31/2007. OMB 0651-0021

U. S. PATENT AND TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE

ATTORNEY'S DOCKET NUMBER

(Longbuler generated form Junis Letter (DO-EO-US)" (PCT Folder), Merck & Co., Inc., 07/08/2005

21300YP

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/554186	
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED	
PCT/US04/012157	20 April 2004	24 April 2003	
TITLE OF INVENTION INHIBITORS OF AKT ACTIVITY			
APPLICANT(S) FOR DO/EO/US			
Mark T. Bilodeau, Craig W. Lindsley, Zhijian Zhao			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1. X This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.			
4. X The US has been elected (PCT Article 31).			
5. A copy of the International Application as filed [35 U.S.C. 371(c)(2)]			
a. is attached hereto (required only if not communicated by the International Bureau).			
b. has been communicated by the International Bureau.			
c. X is not required, as the application was filed in the United States Receiving Office (RO/US).			
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)]. a. is attached hereto			
b. has been previously submitted under 35 U.S.C. 154(d)(4).			
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)]. a. are attached hereto (required only if not communicated by the International Bureau).			
b. have been communicated by the International Bureau.			
c. have not been made; however, the time limit for making such amendments has NOT expired.			
d. X have not been made and will not be made.			
8. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].			
9. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].			
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)]. Items 11 to 20 below concern other document(s) or information included:			
11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
<u> </u>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31		
is included. 13. A preliminary amendment.			
	4. An Application Data Sheet under 37 CFR 1.76.		
15. A substitute specification.			
16. A power of attorney and/or change of address letter.			
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.			
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).			
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).			
20. Other items or information:		PONDENCE IS TATES POSTAL E TO ADDRESSEP ADDRESSED TO	

Approved for use through 3/31/2007. OMB 0651-0021 JCO9 Rec'd PCT/PTO 21 OCT 201 ATTORNEY'S DOCKET NUMBER INTERNATIONAL APPLICATION NO. U.S. APILICATION NO. (If known, see 37 CFR 1.5) 1554186 21300YP PCT/US04/012157 The following fees are submitted: CALCULATIONS PTO USE ONLY X Basic national fee.....\$300 \$300.00 Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)..... All other situations......\$200 \$0.00 Search fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)......\$0 Search fee [37 CFR 1.445(a)(2)] has been paid on the international application to the USPTO as an \$0.00 International Search Report prepared by an ISA other than the US and provided to the Office or TOTAL OF 21, 22 and 23= \$300.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. Number of each additional 50 or fraction **Total Sheets** Extra Sheets **RATE** thereof (round up to a whole number) - 100 = 0 /50 Х \$250.00 \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date [37 CFR 1.492(e)] CLAIMS NUMBER FILED NUMBER EXTRA **RATE** Total Claims - 20 = 19 x \$0.00 \$50.00 Independent Claims X - 3 = 0 \$200.00 \$0.00 MULTIPLE DEPENDENT CLAIM(S) (if applicable) \$360.00 \$300.00 TOTAL OF ABOVE CALCULATIONS (SUBTOTAL) Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)) TOTAL NATIONAL FEE = \$300.00 Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. = TOTAL FEES ENCLOSED \$300.00 Amount to be refunded: Amount to be charged: A check in the amount of \$ _ to cover the above fees is enclosed. Please charge my Deposit Account No. 13-2755 in the amount of \$300.00 to cover the above fees. A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer No. 000210 MERCK & CO., INC. Patent Department, RY60-30 P.O. Box 2000 126 East Lincoln Avenue Rahway, New Jersey 07065-0970 Matthew A. Leff **NAME** DATE: October 21, 2005 50,149 PHONE #: (732) 594-1404 REGISTRATION NUMBER

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 37

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mark T. Bilodeau, et al.

Art Unit:

Attorney Docket No.

21300YP

To be determined

PCT Appl. No.:

PCT/US04/012157

Examiner:

To be determined

Filing Date:

October 21, 2005

For:

INHIBITORS OF AKT ACTIVITY

Mail Stop: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

LETTER

Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21300YP.

DATE OF DEPOSIT DC+ .21

EXPRESS MAIL NO 2/42/5/ I HEREBY CERTIFY THAT THIS CORRE BEING DEPOSITED WITH THE UNITED STATES POSTAL ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO

Respectfully submitted,

Filed: 20 April 2004

Matthew A. Leff

Registration No. 50,149 Attorney for Applicants

Merck & Co., Inc.

P.O. Box 2000 - RY 60-30

Rahway, New Jersey 07065-0907

Telephone No. (732) 594-1404

Date: October 21, 2005